Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's partnership discussions with third parties with respect to the development and commercialization of LX1032.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, including with respect to LX1032, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whethe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... ST. LOUIS, Dec. 21, 2010 Pepex Biomedical, ... solution for insulin dependent diabetics which will combine ... sufferers worldwide.  The company is developing a complete ... testing of blood glucose levels and insulin delivery, ...
... Reportlinker.com announces that a new market research report ... Cyclohexane: 2010 World Market Outlook And Forecast ... market research features all the important sides of ... focusing on the world market, regional and countries, ...
Cached Medicine Technology:Pepex™ Unveils Development of First All-In-One Blood Glucose Meter 2Reportlinker Adds Cyclohexane: 2010 World Market Outlook And Forecast 2
(Date:7/30/2014)... Researchers at the Monterey Bay Aquarium Research Institute (MBARI) ... four and one half yearslonger than any other known ... clean and guarded them from predators. This amazing feat ... the young octopuses of having plenty of time to ... survive for years with little or no food. , ...
(Date:7/30/2014)... 30, 2014 Frozen shoulder (Adhesive capsulitis) affects ... to develop this nasty condition which occurs most frequently in ... last up to two and half years if not treated. ... and with good reason: it can render your shoulder so ... is, if you aren't in too much pain to get ...
(Date:7/30/2014)... (HealthDay News) -- For patients with asthma, just believing ... airway inflammation for at least 24 hours, a new ... but also what you think you smell," study author ... in Philadelphia, said in a Monell news release. ... When we expect that an odor is harmful, our ...
(Date:7/30/2014)... --,Although the vast majority of kids with autism have ... differently from children who have trouble processing sensory stimuli, ... can be overly sensitive to sound, sight and touch. ... a lack of concentration. Complicating matters, some kids ... have trouble tolerating loud noises, like a vacuum. Others ...
(Date:7/30/2014)... adults who were breastfed for three months or ... of chronic inflammation associated with cardiovascular and metabolic ... at Washington University in St. Louis. , "This ... implications for children,s health decades later," said Molly ... School and a co-author of the study with ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2
... ... Dr. Howard Herman, M.D., a physician with the Atlanta Snoring Institute, ... importance of paying attention to sinus pain in order to prevent infection, ... nose, and throat doctor and head and neck surgeon at the Atlanta ...
... ... Hearing Healthcare Provider , ... Bonita Springs, FL (PRWEB) October 28, 2009 -- PHSI (Physician Hearing ... ophthalmologists with the tools needed to care for an ever-growing demographic of patients. ...
... ... platforms , ... -- New York Merchants Protective Co., Inc. , is proud to announce it will ... . , , , , ,NYMPC has been approved as an authorized Geutebruck solutions provider, ...
... , OAK BROOK, Ill., Oct. 28 Understanding the ... for health care providers, including enhancing safety and helping ... malpractice litigation. In fact, many academic medical centers are ... to improve the quality of care for patients. ...
... 27 Addus HomeCare Corporation announced today that it has ... common stock at $10.00 per share. Addus shares will ... Market under the ticker symbol "ADUS". The closing of ... 2009. Addus expects to receive net proceeds from the ...
... , TUESDAY, Oct. 27 (HealthDay News) -- Combining chemotherapy ... neck cancer increases their event-free survival to 2.2 years ... new study. , According to the study authors, "events" ... researchers looked at the 10-year outcomes of 966 patients ...
Cached Medicine News:Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 2Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 3Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 4Health News:PHSI, INC. Develops Revolutionary Vision-Hearing Program 2Health News:New York Merchants Protective Co. Designated as Authorized Geutebruck Solutions Provider 2Health News:New York Merchants Protective Co. Designated as Authorized Geutebruck Solutions Provider 3Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 2Health News:UHC Benchmarking Project Focuses on Patient- and Family-Centered Care in Academic Medical Centers 3Health News:Addus HomeCare Corporation Prices Initial Public Offering 2Health News:Adding Chemo Helps Head, Neck Cancer Patients 2
... Enzyme-linked immunosorbent assay method for ... autoantibodies to myeloperoxidase in human serum. ... can be used as an aid ... and other conditions associated with elevated ...
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
Anti-RSV IgA Assay (ELISA)....
Medicine Products: